TESULOID
LOE ApproachingNDAINJECTION, ORALSOLUTION
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESULOID is an injection and oral solution approved in 1974 by Bracco with unknown mechanism of action and indication profile. The product's exact therapeutic use and pharmacologic class remain unspecified in available data. Patient population and clinical utility cannot be determined from current information.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial data; limited team expansion expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TESULOID presents limited career development potential given zero linked job postings and approaching LOE status. Professionals assigned to this product should expect a defensive, cost-containment focus rather than growth-oriented commercial strategies.
Brand ManagerMarket Access Manager
Worked on TESULOID at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.